Multiple sclerosis, discovered “malignant” molecules for more targeted treatments
A TEAM of researchers from the University of Verona has identified the “malignant” molecules that indicate the most serious stage of multiple sclerosis. In clinical practice, the discovery will allow the neurologist to choose the most appropriate therapy for each patient from the beginning, reserving the most “energetic” for those who really need it.
The discovery is the result of the work of an international team coordinated by Massimiliano Calabrese, professor of neurology of the neuroscience, biomedicine and movement department of the University of Verona, who worked in collaboration with Roberta Magliozzi, the first research signature, and the departments’ teams of neurology B and neuropathology of the Policlinico di Borgo Roma directed by Salvatore Monaco. “Today, to diagnose a multiple sclerosis to a patient – explains Calabrese – a sample is taken of the spleen mullet liquid that surrounds and crosses the entire central nervous system, called ‘liquor’.
READS Hope for anti-sclerosis action, discovering a key protein
“Our research group – continues Calabrese – has developed a new method able to determine in just 24 hours the liquor profile of the ‘malignant’ forms of the disease, that is, with a greater neurodegenerative component, in this way – continues – we can establish, already at the time of diagnosis, therefore at a very early stage, if the patient will face a high risk of progression of the disease and, consequently, identify the best therapy to intervene effectively.This new system will allow us to avoid therapies aggressive not necessary
and therefore unnecessary risks for the patient, but also a consequent considerable savings for the national health system. ”
Multiple sclerosis affects almost 3 million people worldwide – 114 thousand in Italy, of which 9 thousand in Veneto, with over 250 new cases every year.